[Liver damage in hormone therapy of prostate cancer].
The behaviour of the transaminases under contra-sexual initial treatment of the carcinoma of the prostate gland with Cytonal in contrast to Turisteron was compared. In these cases under the Cytonal therapy as an expression of the hepatotoxic side effects a double as high serum activity of the transaminase ALAT could be proved compared with the serum activity of the patients treated with Turisteron. Due to the good tolerability and the only insignificant hepatotoxic reactions Turisteron is well suited for the long-term treatment of the carcinoma of the prostate gland.
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; C025723:ethinyl estradiol sulfonate; D004997:Ethinyl Estradiol; D004054:Diethylstilbestrol; C004955:fosfestrol
Leberschäden unter der Hormontherapie des Prostatakarzinoms.